+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report

  • 180 Pages
  • December 2023
  • Region: Global
  • Infinium Global Research
  • ID: 5557586
Description Jump to:
The report on the global RNAi therapeutics market provides qualitative and quantitative analysis for the period from 2021-2030. The global RNAi therapeutics market was valued at USD 11.20 billion in 2022 and is expected to reach USD 20.23 billion in 2030, with a CAGR of a 7.69% during the forecast period 2023-2030. The study on RNAi therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

The report on RNAi therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global RNAi therapeutics market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global RNAi therapeutics market over the period of 2021-2030. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • The substantial growth in the RNAi therapeutics market is strongly influenced by heightened research and development efforts aimed at addressing chronic diseases.
  • The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market.

2) Restraints

  • Complex delivery mechanisms hinder RNAi therapeutics market.

3) Opportunities

  • Technological breakthroughs in delivery technology have increased the number of indications for RNAi therapeutics, provides an opportunity for the market to grow.

Research Methodology

A) Primary Research

The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global RNAi therapeutics market is segmented on the basis of type, application, route of administration, and end user.

The Global RNAi Therapeutics Market by Type

  • Small interfering RNA (siRNA)
  • MicroRNA (miRNA)

The Global RNAi Therapeutics Market by Application

  • Genetic Disorders
  • Oncology
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Renal Diseases
  • Others

The Global RNAi Therapeutics Market by Route of Administration

  • Intradermal Injections
  • Pulmonary Delivery
  • Intravenous Injections

The Global RNAi Therapeutics Market by End User

  • Diagnostic Laboratories
  • Research and Academic Laboratories
  • Hospitals

Company Profiles

The companies covered in the report include
  • Alnylam Pharmaceuticals, Inc.
  • QIAGEN
  • Olix Pharmaceuticals, Inc.
  • Arbutus Biopharma
  • Silence Therapeutics
  • Dicerna Pharmaceuticals, Inc
  • Arrowhead Pharmaceuticals, Inc.
  • Quark Software Inc.
  • Phio Pharmaceuticals
  • Benitec Biopharma Ltd

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the RNAi therapeutics market.
2. Complete coverage of all the segments in the RNAi therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global RNAi therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
Chapter 2. Executive Summary
2.1. RNAi Therapeutics Market Highlights
2.2. RNAi Therapeutics Market Projection
2.3. RNAi Therapeutics Market Regional Highlights
Chapter 3. Global RNAi Therapeutics Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Type
3.4.2. Growth Matrix Analysis by Application
3.4.3. Growth Matrix Analysis by Route Of Administration
3.4.4. Growth Matrix Analysis by End User
3.4.5. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of RNAi Therapeutics Market
Chapter 4. RNAi Therapeutics Market Macro Indicator Analysis
Chapter 5. Company Profiles and Competitive Landscape
5.1. Competitive Landscape in the Global RNAi Therapeutics Market
5.2. Companies Profiles
5.2.1. Alnylam Pharmaceuticals, Inc.
5.2.2. QIAGEN
5.2.3. Olix Pharmaceuticals, Inc.
5.2.4. Arbutus Biopharma
5.2.5. Silence Therapeutics
5.2.6. Dicerna Pharmaceuticals, Inc
5.2.7. Arrowhead Pharmaceuticals, Inc.
5.2.8. Quark Software Inc.
5.2.9. Phio Pharmaceuticals
5.2.10. Benitec Biopharma Ltd
Chapter 6. Global RNAi Therapeutics Market by Type
6.1. Small interfering RNA (siRNA)
6.2. MicroRNA (miRNA)
Chapter 7. Global RNAi Therapeutics Market by Application
7.1. Genetic Disorders
7.2. Oncology
7.3. Neurodegenerative Disorders
7.4. Infectious Diseases
7.5. Renal Diseases
7.6. Others
Chapter 8. Global RNAi Therapeutics Market by Route Of Administration
8.1. Intradermal Injections
8.2. Pulmonary Delivery
8.3. Intravenous Injections
Chapter 9. Global RNAi Therapeutics Market by End User
9.1. Diagnostic Laboratories
9.2. Research and Academic Laboratories
9.3. Hospitals
Chapter 10. Global RNAi Therapeutics Market by Region 2023-2030
10.1. North America
10.1.1. North America RNAi Therapeutics Market by Type
10.1.2. North America RNAi Therapeutics Market by Application
10.1.3. North America RNAi Therapeutics Market by Route Of Administration
10.1.4. North America RNAi Therapeutics Market by End User
10.1.5. North America RNAi Therapeutics Market by Country
10.1.5.1. The U.S. RNAi Therapeutics Market
10.1.5.1.1. The U.S. RNAi Therapeutics Market by Type
10.1.5.1.2. The U.S. RNAi Therapeutics Market by Application
10.1.5.1.3. The U.S. RNAi Therapeutics Market by Route Of Administration
10.1.5.1.4. The U.S. RNAi Therapeutics Market by End User
10.1.5.2. Canada RNAi Therapeutics Market
10.1.5.2.1. Canada RNAi Therapeutics Market by Type
10.1.5.2.2. Canada RNAi Therapeutics Market by Application
10.1.5.2.3. Canada RNAi Therapeutics Market by Route Of Administration
10.1.5.2.4. Canada RNAi Therapeutics Market by End User
10.1.5.3. Mexico RNAi Therapeutics Market
10.1.5.3.1. Mexico RNAi Therapeutics Market by Type
10.1.5.3.2. Mexico RNAi Therapeutics Market by Application
10.1.5.3.3. Mexico RNAi Therapeutics Market by Route Of Administration
10.1.5.3.4. Mexico RNAi Therapeutics Market by End User
10.2. Europe
10.2.1. Europe RNAi Therapeutics Market by Type
10.2.2. Europe RNAi Therapeutics Market by Application
10.2.3. Europe RNAi Therapeutics Market by Route Of Administration
10.2.4. Europe RNAi Therapeutics Market by End User
10.2.5. Europe RNAi Therapeutics Market by Country
10.2.5.1. Germany RNAi Therapeutics Market
10.2.5.1.1. Germany RNAi Therapeutics Market by Type
10.2.5.1.2. Germany RNAi Therapeutics Market by Application
10.2.5.1.3. Germany RNAi Therapeutics Market by Route Of Administration
10.2.5.1.4. Germany RNAi Therapeutics Market by End User
10.2.5.2. United Kingdom RNAi Therapeutics Market
10.2.5.2.1. United Kingdom RNAi Therapeutics Market by Type
10.2.5.2.2. United Kingdom RNAi Therapeutics Market by Application
10.2.5.2.3. United Kingdom RNAi Therapeutics Market by Route Of Administration
10.2.5.2.4. United Kingdom RNAi Therapeutics Market by End User
10.2.5.3. France RNAi Therapeutics Market
10.2.5.3.1. France RNAi Therapeutics Market by Type
10.2.5.3.2. France RNAi Therapeutics Market by Application
10.2.5.3.3. France RNAi Therapeutics Market by Route Of Administration
10.2.5.3.4. France RNAi Therapeutics Market by End User
10.2.5.4. Italy RNAi Therapeutics Market
10.2.5.4.1. Italy RNAi Therapeutics Market by Type
10.2.5.4.2. Italy RNAi Therapeutics Market by Application
10.2.5.4.3. Italy RNAi Therapeutics Market by Route Of Administration
10.2.5.4.4. Italy RNAi Therapeutics Market by End User
10.2.5.5. Rest of Europe RNAi Therapeutics Market
10.2.5.5.1. Rest of Europe RNAi Therapeutics Market by Type
10.2.5.5.2. Rest of Europe RNAi Therapeutics Market by Application
10.2.5.5.3. Rest of Europe RNAi Therapeutics Market by Route Of Administration
10.2.5.5.4. Rest of Europe RNAi Therapeutics Market by End User
10.3. Asia Pacific
10.3.1. Asia Pacific RNAi Therapeutics Market by Type
10.3.2. Asia Pacific RNAi Therapeutics Market by Application
10.3.3. Asia Pacific RNAi Therapeutics Market by Route Of Administration
10.3.4. Asia Pacific RNAi Therapeutics Market by End User
10.3.5. Asia Pacific RNAi Therapeutics Market by Country
10.3.5.1. China RNAi Therapeutics Market
10.3.5.1.1. China RNAi Therapeutics Market by Type
10.3.5.1.2. China RNAi Therapeutics Market by Application
10.3.5.1.3. China RNAi Therapeutics Market by Route Of Administration
10.3.5.1.4. China RNAi Therapeutics Market by End User
10.3.5.2. Japan RNAi Therapeutics Market
10.3.5.2.1. Japan RNAi Therapeutics Market by Type
10.3.5.2.2. Japan RNAi Therapeutics Market by Application
10.3.5.2.3. Japan RNAi Therapeutics Market by Route Of Administration
10.3.5.2.4. Japan RNAi Therapeutics Market by End User
10.3.5.3. India RNAi Therapeutics Market
10.3.5.3.1. India RNAi Therapeutics Market by Type
10.3.5.3.2. India RNAi Therapeutics Market by Application
10.3.5.3.3. India RNAi Therapeutics Market by Route Of Administration
10.3.5.3.4. India RNAi Therapeutics Market by End User
10.3.5.4. South Korea RNAi Therapeutics Market
10.3.5.4.1. South Korea RNAi Therapeutics Market by Type
10.3.5.4.2. South Korea RNAi Therapeutics Market by Application
10.3.5.4.3. South Korea RNAi Therapeutics Market by Route Of Administration
10.3.5.4.4. South Korea RNAi Therapeutics Market by End User
10.3.5.5. Australia RNAi Therapeutics Market
10.3.5.5.1. Australia RNAi Therapeutics Market by Type
10.3.5.5.2. Australia RNAi Therapeutics Market by Application
10.3.5.5.3. Australia RNAi Therapeutics Market by Route Of Administration
10.3.5.5.4. Australia RNAi Therapeutics Market by End User
10.3.5.6. Rest of Asia-Pacific RNAi Therapeutics Market
10.3.5.6.1. Rest of Asia-Pacific RNAi Therapeutics Market by Type
10.3.5.6.2. Rest of Asia-Pacific RNAi Therapeutics Market by Application
10.3.5.6.3. Rest of Asia-Pacific RNAi Therapeutics Market by Route Of Administration
10.3.5.6.4. Rest of Asia-Pacific RNAi Therapeutics Market by End User
10.4. RoW
10.4.1. RoW RNAi Therapeutics Market by Type
10.4.2. RoW RNAi Therapeutics Market by Application
10.4.3. RoW RNAi Therapeutics Market by Route Of Administration
10.4.4. RoW RNAi Therapeutics Market by End User
10.4.5. RoW RNAi Therapeutics Market by Sub-region
10.4.5.1. Latin America RNAi Therapeutics Market
10.4.5.1.1. Latin America RNAi Therapeutics Market by Type
10.4.5.1.2. Latin America RNAi Therapeutics Market by Application
10.4.5.1.3. Latin America RNAi Therapeutics Market by Route Of Administration
10.4.5.1.4. Latin America RNAi Therapeutics Market by End User
10.4.5.2. Middle East RNAi Therapeutics Market
10.4.5.2.1. Middle East RNAi Therapeutics Market by Type
10.4.5.2.2. Middle East RNAi Therapeutics Market by Application
10.4.5.2.3. Middle East RNAi Therapeutics Market by Route Of Administration
10.4.5.2.4. Middle East RNAi Therapeutics Market by End User
10.4.5.3. Africa RNAi Therapeutics Market
10.4.5.3.1. Africa RNAi Therapeutics Market by Type
10.4.5.3.2. Africa RNAi Therapeutics Market by Application
10.4.5.3.3. Africa RNAi Therapeutics Market by Route Of Administration
10.4.5.3.4. Africa RNAi Therapeutics Market by End User

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • QIAGEN
  • Olix Pharmaceuticals, Inc.
  • Arbutus Biopharma
  • Silence Therapeutics
  • Dicerna Pharmaceuticals, Inc
  • Arrowhead Pharmaceuticals, Inc.
  • Quark Software Inc.
  • Phio Pharmaceuticals
  • Benitec Biopharma Ltd

Table Information

Report AttributeDetails
No. of Pages180
PublishedDecember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 11.2 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.23 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Antisense & RNAi Therapeutics Market by Technology (Antisense RNA, RNA Interference), Application (Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases), Route of Administration - Forecast 2024-2030 - Product Image

Global Antisense & RNAi Therapeutics Market by Technology (Antisense RNA, RNA Interference), Application (Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases), Route of Administration - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Global Antisense and RNAi Therapeutics Market - Product Image

Global Antisense and RNAi Therapeutics Market

  • Report
  • 200 Pages
  • Global
From
Antisense & RNAi Therapeutics Global Market Report 2024 - Product Image

Antisense & RNAi Therapeutics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route of Administration (Intrathecal, Intravenous), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route of Administration (Intrathecal, Intravenous), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 130 Pages
  • Global
From
Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 143 Pages
  • Global
From

About the RNAi Therapy Market

RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes. RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings. Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.